If you like to see how the sausage is made, Seeking Alpha takes a look inside Geron, a company representative of the messy business of developing the latest regenerative medicine and cancer therapies: "Geron has two telomerase-based cancer drugs in human trials, though both are early stage. For metastatic prostate cancer, the company is injecting telomerase into patients, hoping to provoke a more aggressive immune response - a therapeutic vaccine. ... On the stem cell front, Geron is testing GRNOPC1 to treat spinal cord injuries. The drug was given to rats with injuries that prevented them from using their legs, and GRNOPC1 helped them regain control of their legs. ... A second drug, GRNIC1, uses embryonic stem cell-derived islet clusters treatment to treat diabetes. ... Geron plans to begin its initial human testing of the drug in 2007 ... GRNCM1, the third stem cell based drug candidate, is a potential treatment for myocardial infarction."
28
Dec
2006
A Look Inside Geron
Comments
Post a comment; thoughtful, considered opinions are valued. Please note that comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.
First Steps
The Causes of Aging
- Accumulating AGEs
- Buildup of Amyloid Between Cells
- The Failing Adaptive Immune System
- The Failing Innate Immune System
- Declining Lysosomal Function
- Mitochondrial DNA Damage
- Nuclear DNA Damage
- Buildup of Senescent Cells
- Other Causes of Aging
Archives and Feeds
- Monthly News and Blog Archives
- Newsletter Archive
- Using the Fight Aging! Content Feeds
- Fight Aging! on the Kindle
Required Reading
- Calorie Restriction
- The Community, Visualized
- Cryonics
- Engineered Negligible Senescence
- Envisaging a World Without the FDA
- How to Argue for Longevity Science
- Introductory Articles
- The Odds of Human Longevity Mutations
- The Need For Activism and Advocacy
- Stem Cells, Regenerative Medicine
- Twelve Ways to Extend Mouse Life Span
- Transhumanism and Human Longevity
- The Vital Debate in Aging Research
- What is Anti-Aging?
Creative Commons
- All of Fight Aging!, with the exception of the introductory articles, is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite Creative Commons licensed Fight Aging! content in any way you see fit, the only requirements being that you (a) link to the original, (b) attribute the author, and (c) attribute Fight Aging!.